- ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
- Lilly and ProQR to Expand RNA Editing Collaboration
- ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
- ProQR Announces Third Quarter 2022 Operating and Financial Results
- ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
- ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
- ProQR Announces Second Quarter 2022 Operating and Financial Results
- ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
- ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
- ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
More ▼
Key statistics
On Friday, ProQR Therapeutics NV (PRQR:NAQ) closed at 3.15, 494.34% above the 52 week low of 0.530 set on May 11, 2022.
52-week range
Markit short selling activity
Open | 2.85 |
---|---|
High | 3.23 |
Low | 2.82 |
Bid | 3.08 |
Offer | 3.15 |
Previous close | 2.85 |
Average volume | 1.12m |
---|---|
Shares outstanding | 71.43m |
Free float | 62.46m |
P/E (TTM) | -- |
Market cap | 225.02m USD |
EPS (TTM) | -1.09 USD |
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.
More ▼